Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial.
Two SGLT2 inhibitors differed in urinary-tract-infection rates among diabetic women, potentially helping patients and doctors choose between them.
A small double-blind trial compared urinary tract infection rates between two SGLT2 inhibitors in women with diabetes. The result may inform drug choice, but the short follow-up and modest sample constrain generalizability.
What the study was
- Study design
- Double-blind randomized clinical trial
- Population
- Women with diabetes receiving dapagliflozin or empagliflozin
- Sample size
- 149
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International journal of endocrinology and metabolism
Why it surfaced
Randomization strengthens the comparison, but the trial is small, short, and focused on one safety outcome.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.